Axicabtagene ciloleucel - Kite Pharma

Drug Profile

Axicabtagene ciloleucel - Kite Pharma

Alternative Names: Axi-cel; KTE-C19; KTE-C19 CAR; Yescarta

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cabaret Biotech
  • Developer Daiichi Sankyo Inc; Genentech; H. Lee Moffitt Cancer Center and Research Institute; Kite Pharma; National Cancer Institute (USA)
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed B cell lymphoma; Diffuse large B cell lymphoma
  • Preregistration Follicular lymphoma
  • Phase II Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Leukaemia

Most Recent Events

  • 29 Jun 2018 Committee for Medicinal Products for Human Use issued a positive opinion for axicabtagene ciloleucel for diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in European union
  • 04 Jun 2018 Updated new efficacy and safety data from the phase I/II ZUMA-3 trial in Acute lymphoblastic leukaemia released by Kite Pharma
  • 04 Jun 2018 Updated new efficacy data from the phase I/II ZUMA-1 trial for B-cell lymphoma released by Kite Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top